
The Alzheimer Society Research Portal connects researchers with Canadians looking to participate in research studies. On this website, find active studies that you can participate in to help advance research on dementia.
Participants will receive drug treatment via IV in clinic on Day 1 and every 4 weeks thereafter.
Multi-center, Double-Blind, Placebo-Controlled Phase 1/2 Trial to Assess the Safety and Tolerability of WVE-3972-01 Administered Intrathecally to Patients with Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD).
A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer's Disease (AD), Followed by an Open-Label Extension Period.
A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE).
A Phase 3 randomized double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus)
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease
The Health in Aging, Neurodegenerative Diseases and Dementias in Ontario (HANDDS-ONT) Study is an observational study that takes place in the comfort of participant’s home, with no study visits occurring in a clinic. The study is recruiting people living with and without a neurodegenerative disease (see below) or the effects of stroke. Studying both groups will help ONDRI researchers to:
All data collected will be anonymized and will be stored securely by the Ontario Brain Institute.
The Rare Dementia Support Impact Study is a cross-national 5-year collaboration between Nipissing University, Canada; University College London (UCL), England; and Bangor University, Wales, and the world’s largest study on rare dementia support. More than 5% of people living with dementia have a rare or young onset type, which is not well understood.
This is a phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study that will assess efficacy and safety of AL002 administered intravenously (IV) in participants with Early Alzheimer's Disease.
Follow us: